Malignant melanoma accounts for less than 2% of all penile malignancies — and a new case report published in Cureus documents one of these exceptionally rare tumors, adding to a clinical literature that remains dominated by single-case descriptions.

The report, titled "Malignant Melanoma as a Rare Cause of Penile Cancer: A Case Report," concerns primary melanoma arising at a mucocutaneous site where squamous cell carcinoma is overwhelmingly the dominant histology. Penile cancer itself is uncommon; melanoma of the penis is rarer still, and management guidance rests almost entirely on case series and retrospective review rather than prospective trials.

Why does the diagnosis matter?

For dermatologists and urologists, penile melanoma illustrates the diagnostic challenge of pigmented lesions at genital and mucosal sites. These tumors frequently present at an advanced stage, in part because patients delay presentation and because lesions at this location are often not examined routinely. Histopathology, not visual inspection, establishes the diagnosis.

Standard reporting for cutaneous melanoma — Breslow thickness, ulceration status, mitotic rate and AJCC staging — guides prognosis and surgical planning in penile disease as well, although the anatomical constraints of the site complicate wide local excision and sentinel lymph node mapping. The Cureus report contributes another documented case to that small evidence base.

How rare is the entity?

Genital melanoma in total represents a small fraction of all melanomas, and penile localization is the least common subsite within that group. Published estimates consistently place primary penile melanoma below 2% of penile cancers, with squamous cell carcinoma comprising the vast majority of the remainder.

Because incidence is so low, no randomized data exist to define optimal margins, lymph node management or adjuvant therapy. Case reports such as this one serve a specific function: they consolidate clinical presentation, histologic confirmation and treatment course so that accumulating experience can eventually support consensus recommendations.

What should clinicians take from the report?

The case underscores two practical points for skin-cancer practice:

• Any pigmented lesion on the penis that changes, ulcerates, bleeds or shows irregular pigmentation warrants biopsy, not observation.
• Dermatologists should include genital skin in full-body skin examinations, a site routinely under-examined despite its prognostic stakes.

Late diagnosis remains the principal driver of poor outcomes in penile melanoma, and complete skin examination is the one intervention squarely within dermatology's control.

As case-level documentation accumulates in journals such as Cureus, clinicians can expect progressively clearer — if still retrospective — guidance on staging workup and surgical management for this rare malignancy.